CONCORD, Ohio--(BUSINESS WIRE)--Ricerca Biosciences, an integrated preclinical pharmaceutical contract research organization (CRO), today announced the introduction of two new state-of-the-art cellular assay services: Early Safety Screening Cytotoxicity and ImmunoSIGNAL™ Cytokine Storm Cellular Assay.
